Zhang et al. show that genetically simulated IL-6 inhibition is associated with a reduced risk of cardiovascular disease and no increase in infection risk, supporting the use of emerging pharmacological treatments targeting IL-6 rather than its receptor. Here, IL6 is linked to infection.